Trial reportDiabetes care2001
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Trial report in Diabetes care, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000542. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.The Cochrane database of systematic reviews · 2018Pooled it
- Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study.Journal of clinical hypertension (Greenwich, Conn.) · 2004 · on this mapTrial
- First-line diuretics versus other classes of antihypertensive drugs for hypertension.The Cochrane database of systematic reviews · 2023Review
- Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines.Clinical kidney journal · 2017Article
- Hypertension in Non-Type 2 Diabetes in Isfahan, Iran: Incidence and Risk Factors.International journal of hypertension · 2017Article
- Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management.Current hypertension reports · 2004Review
- Adding low-dose spironolactone to multidrug regimens for resistant hypertension.Current hypertension reports · 2004Article
- Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study.The pharmacogenomics journal · 2002Article
- Treatment of coexisting diabetes and hypertension.Current cardiology reports · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHypertension (HTN) is a major risk factor for cardiovascular disease (CVD) in the setting of diabetes. There is no consensus on how best to treat hypertension among those with diabetes. Here we describe the characteristics of a cohort of hypertensive adults with diabetes who are part of a large prospective blood pressure study. This study will help clarify the treatment of HTN in the setting of diabetes. RESEARCH DESIGN AND
methodsThe Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin). The planned follow-up is an average of 6 years, to be completed March 2002.
resultsThere are 15,297 diabetic individuals in the ALLHAT study (36.0% of the entire cohort). Of these individuals, 50.2% are male, 39.4% are African-American, and 17.7% are Hispanic. Demographic and laboratory characteristics of the cohort are similar to those of other studies of the U.S. elderly population with HTN. The sample size has 42 and 93% confidence, treatments for the two study outcomes.
conclusionsThe diabetic cohort in ALLHAT wil be able to provide valuable information about the treatment of hypertension in older diabetic patients at risk for incident CVD.
Indexed as
Identifiers
11315826What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.